• CRISPR Therapeutics AG CRSP.OQ reported a quarterly adjusted loss of $1.58​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of $-1.43. The mean expectation of twenty analysts for the quarter was for a loss of $1.25 per share. Wall Street expected results to range from $-1.74 to -74 cents per share.

• Revenue rose 71.6% to $865.00 thousand from a year ago; analysts expected $6.50 million.

• CRISPR Therapeutics AG's reported EPS for the quarter was a loss of $1.58​.

• The company reported a quarterly loss of $136 million.

• CRISPR Therapeutics AG shares had risen by 10.5% this quarter and lost 4.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 7.5% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 11 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for CRISPR Therapeutics AG is $77.50

This summary was machine generated from LSEG data May 6 at 08:55 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)